Biological Availability - Research News and Information

Thursday, January 08, 2009

Antitumor efficacy testing in rodents.

26 Oct 2008 The preclinical research and human clinical trials necessary for developing anticancer therapeutics are costly. One contributor to these costs is preclinical rodent efficacy studies, which, in addition to the costs associated with conducting them, ... Read more...

The sweet life: diet sugar concentration influences paracellular glucose absorption.

21 Oct 2008 Small birds and bats face strong selection pressure to digest food rapidly in order to reduce digesta mass carried during flight. One mechanism is rapid absorption of a high proportion of glucose via the paracellular pathway (transfer between ... Read more...

[Reasons for proton-pump-inhibitor failure in the treatment of gastroesophageal reflux disease]

3 Oct 2008 The introduction of proton pump inhibitors (PPI) has facilitated the successful management of patients with gastroesophageal reflux disease (GERD). In a minor, but still relevant proportion of patients with GERD-like symptoms, PPI therapy has also ... Read more...

Learn Faster Today      Improve your study skills

Latest indexed articles for 'Biological Availability'

These are the very latest articles for this heading:

• Antitumor efficacy testing in rodents. 26 Oct 2008
• The sweet life: diet sugar concentration influences paracellular glucose absorption. 21 Oct 2008
• [Reasons for proton-pump-inhibitor failure in the treatment of gastroesophageal reflux disease] 3 Oct 2008
• Bioavailability of clarithromycin cyclodextrin ternary complexes upon oral administration to healthy beagle dogs. 29 Sep 2008
• The absorption, distribution, metabolism and elimination of bevirimat in rats. 29 Sep 2008
• Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability. 29 Sep 2008
• Arginine, nitric oxide, carbon monoxide, and endothelial function in severe malaria. 29 Sep 2008
• Effect of adhesive matrix composition and terpinolene on indomethacin bioavailability in rats from transdermal therapeutic system. 29 Sep 2008
• Extended release dosage form of glipizide: development and validation of a level A in vitro-in vivo correlation. 29 Sep 2008
• Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs. 29 Sep 2008
• Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects. 29 Sep 2008
• Manipulation of lipid bioaccessibility of almond seeds influences postprandial lipemia in healthy human subjects. 29 Sep 2008
• Iron metabolism in heterozygotes for hemoglobin E (HbE), alpha-thalassemia 1, or beta-thalassemia and in compound heterozygotes for HbE/beta-thalassemia. 29 Sep 2008
• Preventive effect against post-cataract endophthalmitis: drug delivery intraocular lens versus intracameral antibiotics. 29 Sep 2008
• The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . 23 Sep 2008
• Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain. 23 Sep 2008
• Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. 23 Sep 2008
• A beta-fluoroamine inhibitor of purine nucleoside phosphorylase. 23 Sep 2008
• Arterial compliance and vitamin E blood levels with a self emulsifying preparation of tocotrienol rich vitamin E. 18 Sep 2008
• [Human serum albumin: gene-technological possibilities] 13 Sep 2008

See a longer list of these articles.

Technical information about 'Biological Availability'

Definition: The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action.

Descriptor UI: D001682

Alternative terms: Biological Availability; Availability, Biological; Availabilities, Biological; Biological Availabilities; Biologic Availability; Physiologic Availability; Availability, Biologic; Availabilities, Biologic; Biologic Availabilities; Bioavailability; Bioavailabilities; Availability, Physiologic; Availabilities, Physiologic; Physiologic Availabilities; Availability Equivalency; Availability Equivalencies; Equivalencies, Availability; Equivalency, Availability;

Tree Number: G03.787.151; G07.690.725.129;

Online Note: use BIOLOGICAL AVAILABILITY to search AVAILABILITY EQUIVALENCY 1980-86, BIOLOGIC AVAILABILITY & PHYSIOLOGIC AVAILABILITY 1975-79, & BIOPHARMACEUTICS 1970-74

History Note: 79; was BIOLOGIC AVAILABILITY see under BIOPHARMACEUTICS 1970-78; PHYSIOLOGIC AVAILABILITY was see under BIOPHARMACEUTICS 1970-79; AVAILABILITY EQUIVALENCY was see under BIOPHARMACEUTICS 1970-79 and see under BIOLOGICAL AVAILABILITY 1980-86

Technical Notes: NIM with specific drug /pharmacokin (IM); no qualif; DF: BIOL AVAILABILITY